News - Astellas Pharma

Filter

Current filters:

Astellas Pharma

Popular Filters

40 to 64 of 136 results

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

AVEO Oncology restructuring and job cuts as tivozanib future in RCC in doubt

05-06-2013

Following a recent negative opinion on its lead product candidate from a Food and Drug Administration…

Astellas PharmaAVEO OncologyBiotechnologyFinancialManagementOncologyResearchtivozanib

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

03-06-2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Astellas and Medivation file for approval of enzalutamide in Japan

24-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted an application for marketing approval of…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalRegulationXtandi

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo

16-05-2013

The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially…

AlgetaAstellas PharmaBayerNorth AmericaOncologyPharmaceuticalRegulationXofigo

Astellas reorganizes research framework, including closing OSI Pharma and Perseid

15-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has announced plans to reshape its research framework…

Astellas PharmaFinancialManagementOSI PharmaceuticalsPerseid TherapeuticsPharmaceuticalResearch

Shire's ADHA drug Elvanse accepted for NHS use in Scotland; UK guidance on fidaxomicin

14-05-2013

Ireland-headquartered Shire plc (LSE: SHP) said yesterday (May 13) that its single-daily dose long-acting…

Antibiotics and Infectious diseasesAstellas PharmaDificlirElvanseEuropefidaxomicinNeurologicalPharmaceuticalRegulationShire

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

FDA advisory votes against AVEO and Astellas' cancer drug tivozanib

03-05-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) saw its shares plunge as much as 57% in late trading yesterday…

Astellas PharmaAVEO OncologyBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

IQWiG finds no added proven benefit for Astellas' fidaxomicin in Clostridium difficile infection

23-04-2013

The antibiotic fidaxomicin (trade name: In an early benefit assessment under Germany's Act on the Reform…

Antibiotics and Infectious diseasesAstellas PharmaDificidDificlirEuropefidaxomicinPharmaceuticalPricingRegulation

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin

05-04-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Zeria and Astellas' Acofide approved in Japan for functional dyspepsia

27-03-2013

Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the marketing of Acofide (acotiamide…

AcofideAsia-PacificAstellas PharmaGastro-intestinalsPharmaceuticalRegulationZeria Pharmaceuticals

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes

14-03-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374

12-03-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Astellas starts European roll-out of OAB drug Betmiga in UK

27-02-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has started the European launch…

Astellas PharmaBetmigaEuropeGastro-intestinalsMarkets & MarketingPharmaceutical

40 to 64 of 136 results

Back to top